Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abiomed Inc (ABMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,333,853
  • Shares Outstanding, K 45,086
  • Annual Sales, $ 593,750 K
  • Annual Income, $ 112,170 K
  • 36-Month Beta 0.38
  • Price/Sales 27.29
  • Price/Cash Flow 129.19
  • Price/Book 19.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.07
  • Number of Estimates 7
  • High Estimate 1.13
  • Low Estimate 1.03
  • Prior Year 0.80
  • Growth Rate Est. (year over year) +33.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
316.38 +13.27%
on 02/04/19
364.31 -1.63%
on 02/19/19
+24.62 (+7.38%)
since 01/18/19
3-Month
274.02 +30.78%
on 12/24/18
364.31 -1.63%
on 02/19/19
+56.76 (+18.82%)
since 11/21/18
52-Week
258.10 +38.85%
on 03/01/18
459.75 -22.05%
on 10/01/18
+90.11 (+33.59%)
since 02/21/18

Most Recent Stories

More News
Abiomed (ABMD) Is Up 6.11% in One Week: What You Should Know

Does Abiomed (ABMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

ABMD : 358.36 (-1.07%)
Is Abiomed (ABMD) a Solid Growth Stock? 3 Reasons to Think " Yes "

Abiomed (ABMD) could produce exceptional returns because of its solid growth attributes.

ABMD : 358.36 (-1.07%)
$100 Million Invested in Clinical Research for Impella

In a milestone for scientific research, Abiomed (NASDAQ: ABMD) has now invested more than $100 million over the past five years in clinical research on the Impella heart pump platform....

ABMD : 358.36 (-1.07%)
Has ABIOMED (ABMD) Outpaced Other Medical Stocks This Year?

Is (ABMD) Outperforming Other Medical Stocks This Year?

ABMD : 358.36 (-1.07%)
After Yesterday's Rally of 3.08% Shares Could Potentially Pullback

Abiomed Inc (NASDAQ:ABMD) traded in a range yesterday that spanned from a low of $343.68 to a high of $351.73. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of...

ABMD : 358.36 (-1.07%)
Market Trends Toward New Normal in Wayfair, MSCI, ABIOMED, Arch Coal, Unifi, and NeoPhotonics -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Wayfair Inc. (NYSE:W), MSCI...

ABMD : 358.36 (-1.07%)
W : 117.28 (-0.60%)
MSCI : 174.22 (-1.07%)
ARCH : 91.71 (+0.86%)
NPTN : 7.69 (+0.13%)
UFI : 22.85 (-1.34%)
3 Reasons Why Growth Investors Shouldn't Overlook Abiomed (ABMD)

Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.

ABMD : 358.36 (-1.07%)
Abiomed (ABMD) Upgraded to Buy: What Does It Mean for the Stock?

Abiomed (ABMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ABMD : 358.36 (-1.07%)
ABIOMED (ABMD) Q3 Earnings Beat, Impella Maintains Momentum

ABIOMED's (ABMD) flagship Impella sees a solid Q3; fiscal 2019 outlook raised.

SRDX : 56.41 (-3.14%)
ABMD : 358.36 (-1.07%)
VAR : 131.71 (-0.70%)
ANGO : 22.43 (-4.31%)
Abiomed (ABMD) Tops Q3 Earnings Estimates

Abiomed (ABMD) delivered earnings and revenue surprises of 3.19% and -0.02%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

ABMD : 358.36 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ABMD with:

Business Summary

Abiomed, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing...

See More

Key Turning Points

2nd Resistance Point 364.37
1st Resistance Point 361.36
Last Price 358.36
1st Support Level 356.01
2nd Support Level 353.67

See More

52-Week High 459.75
Fibonacci 61.8% 382.72
Fibonacci 50% 358.92
Last Price 358.36
Fibonacci 38.2% 335.13
52-Week Low 258.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar